CD66a Antilichaam / CEACAM1 / BGP-1

Carcinoembryonic antigen (CEA) is one of the most commonly used tumor markers in serum immunoassay determinations of carcinoma. Members of the CEACAM (carcinoembryonic antigen-related cell adhesion molecule) family contain a single N domain, with structural homology to the immunoglobulin variable domains, followed by a variable number of immunoglobulin constantlike A and/or B domains. CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1), also known as BGP or BGP1, is a 526 amino acid protein that exists as seven alternatively spliced isoforms, some of which localize to the cell membranes, while others are secreted. One of several members of the CEACAM family, CEACAM1 contains one Ig-like V-type domain and three Ig-like C2-type domains and is thought to play a role in a variety of cellular activities, including angiogenesis, apoptosis, arrangement of tissue threedimensional structure and modulation of innate and adaptive immune responses. Additionally, CEACAM1 is underexpressed in colorectal cancers, suggesting a role in tumor suppression.

Western blot: 2-4 µg/mL, Immunohistochemistry (FFPE) : 1-2 µg/mL

P13688

Human

A portion of amino acids 50-250 from human CEACAM1 protein was used as the immunogen for the CD66a antibody.

CEACAM1/12661

WB, IHC-P

Protein G affinity

Purified

This CD66a antibody is available for research use only.

Aliquot the CD66a antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

1 mg/mL in 1X PBS; BSA free, sodium azide free

Optimal dilution of the CD66a antibody should be determined by the researcher.

Secreted, Cell membrane

Western blot testing of human SK-MEL-28 cell lysate with CD66a antibody (clone CEACAM1/12661) . Predicted molecular weight ~58 kDa but may be observed at higher molecular weights due to heavy glycosylation.